Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Last updated: August 21, 2025
Sponsor: Novartis Pharmaceuticals
Overall Status: Terminated

Phase

1

Condition

Esophageal Cancer

Gastrointestinal Diseases And Disorders

Squamous Cell Carcinoma

Treatment

TNO155 in combination with EGF816 (nazartinib)

TNO155

Clinical Study ID

NCT03114319
CTNO155X2101
2023-508925-29-00
2016-001861-10
  • Ages 18-99
  • All Genders

Study Summary

The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Able to understand and voluntarily sign the ICF and able to comply with the studyvisit schedule and the other protocol requirements.

  2. Patient (male or female) ≥18 years of age willing to agree to not father achild/become pregnant and comply with effective contraception criteria.

  3. Must have progressed following standard therapy, or for whom, in the opinion of theInvestigator, no effective standard therapy exists, is tolerated or is appropriate.

  4. ECOG (Eastern cooperative oncology group) performance status ≤2 Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):

  5. Patients must be screened for Hepatitis B virus and Hepatitis C virus

Exclusion

Exclusion Criteria:

  1. Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations. (Exceptions are KRAS G12-mutant NSCLC's)

  2. History or current evidence of retinal vein occlusion (RVO) or current risk factorsfor RVO.

  3. Any medical condition that would, in the investigator's judgment, prevent thepatient's participation in the clinical study due to safety concerns or compliancewith clinical study procedures.

  4. Clinically significant cardiac disease.

  5. Active diarrhea or inflammatory bowel disease

  6. Insufficient bone marrow function

  7. Insufficient hepatic and renal function. Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):

  8. Patients with a known history of human immunodeficiency virus (HIV) seropositivity.

  9. Patients receiving concomitant immunosuppressive agents or chronic corticosteroidsuse at the time of study entry.

  10. Patients who have undergone a bone marrow or solid organ transplant

  11. Patients with a history or presence of interstitial lung disease or interstitialpneumonitis

  12. Bullous and exfoliative skin disorders at screening of any grade

  13. Presence of clinically significant ophthalmological abnormalities that mightincrease the risk of corneal epithelial injury

Study Design

Total Participants: 227
Treatment Group(s): 2
Primary Treatment: TNO155 in combination with EGF816 (nazartinib)
Phase: 1
Study Start date:
May 26, 2017
Estimated Completion Date:
July 04, 2025

Study Description

This study has been designed as a Phase I, open-label, dose finding study with a dose escalation part and a dose expansion part in adult patients with selected advanced solid tumors. The study treatment, TNO155 alone or in combination with EGF816 (nazartinib), was taken until the patient experienced unacceptable toxicity, progressive disease and/or treatment was discontinued at the discretion of the investigator or the patient or due to withdrawal of consent.

Connect with a study center

  • Novartis Investigative Site

    Toronto, Ontario M5G 2M9
    Canada

    Site Not Available

  • Novartis Investigative Site

    Toronto 6167865, Ontario 6093943 M5G 2M9
    Canada

    Site Not Available

  • Novartis Investigative Site

    Milan 6951411, MI 20141
    Italy

    Site Not Available

  • Novartis Investigative Site

    Milano, MI 20141
    Italy

    Site Not Available

  • Novartis Investigational Site

    Kobe,
    Japan

    Site Not Available

  • Novartis Investigative Site

    Kobe 1859171, 650-0017
    Japan

    Site Not Available

  • Novartis Investigative Site

    Kobe shi, 650-0017
    Japan

    Site Not Available

  • Novartis Investigative Site

    Kobe-shi, 650-0017
    Japan

    Site Not Available

  • Novartis Investigative Site

    Seoul, 05505
    Korea, Republic of

    Site Not Available

  • Novartis Investigative Site

    Rotterdam 2747891, South Holland 2743698 3015 GD
    Netherlands

    Site Not Available

  • Novartis Investigative Site

    Rotterdam, Zuid Holland 3015 GD
    Netherlands

    Site Not Available

  • Novartis Investigative Site

    Amsterdam, 1066 CX
    Netherlands

    Site Not Available

  • Novartis Investigative Site

    Amsterdam 2759794, 1066 CX
    Netherlands

    Site Not Available

  • Novartis Investigative Site

    Leiden, 2300 RC
    Netherlands

    Site Not Available

  • Novartis Investigative Site

    Singapore, 168583
    Singapore

    Site Not Available

  • Novartis Investigative Site

    Singapore 1880252, 168583
    Singapore

    Site Not Available

  • Novartis Investigative Site

    Seoul 1835848, 03080
    South Korea

    Site Not Available

  • Novartis Investigative Site

    Hospitalet de LLobregat, Barcelona 08907
    Spain

    Site Not Available

  • Novartis Investigative Site

    L'Hospitalet de Llobregat 3120619, Barcelona 08907
    Spain

    Site Not Available

  • Novartis Investigative Site

    Barcelona 3128760, Catalonia 3336901 08035
    Spain

    Site Not Available

  • Novartis Investigative Site

    Barcelona, Catalunya 08035
    Spain

    Site Not Available

  • Novartis Investigative Site

    Madrid, 28040
    Spain

    Site Not Available

  • Novartis Investigative Site

    Madrid 3117735, 28034
    Spain

    Site Not Available

  • Novartis Investigative Site

    Taipei, 10002
    Taiwan

    Site Not Available

  • Novartis Investigative Site

    Taipei 1668341, 10002
    Taiwan

    Site Not Available

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida 33612
    United States

    Site Not Available

  • H Lee Moffitt Cancer Center and Research Institute .

    Tampa, Florida 33612
    United States

    Site Not Available

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa 4174757, Florida 4155751 33612
    United States

    Site Not Available

  • Dana Farber Cancer Center

    Boston, Massachusetts 02215
    United States

    Site Not Available

  • Novartis Investigative Site

    Boston, Massachusetts 02215
    United States

    Site Not Available

  • Dana Farber Cancer Center

    Boston 4930956, Massachusetts 6254926 02215
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10065
    United States

    Active - Recruiting

  • Memorial Sloane Ketterin Cancer Ctr

    New York, New York 10065
    United States

    Site Not Available

  • Memorial Sloane Ketterin Cancer Ctr Main Centre

    New York, New York 10065
    United States

    Site Not Available

  • Memorial Sloane Kettering Cancer Center Main Centre

    New York, New York 10065
    United States

    Active - Recruiting

  • NYU Langone Health .

    New York, New York 10016
    United States

    Site Not Available

  • Memorial Sloane Ketterin Cancer Ctr

    New York 5128581, New York 5128638 10065
    United States

    Site Not Available

  • Sarah Cannon Research Institute

    Nashville, Tennessee 37221
    United States

    Site Not Available

  • Sarah Cannon Research Institute

    Nashville 4644585, Tennessee 4662168 37221
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.